Physician profile
Christopher R Arico
NPI 1912195058
$406,760.94
in general payments reported to CMS, 2019-2025
22 companies · $144K in 2025
The $144K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31K · 2022: $46K · 2023: $89K · 2024: $97K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $256K · Consulting Fee: $31K · Travel and Lodging: $30K · Food and Beverage: $13K · Education: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $255,679.00 |
| Consulting Fee | $30,523.75 |
| Travel and Lodging | $30,495.40 |
| Food and Beverage | $13,077.36 |
| Education | $470.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169,044.93 | 2021-2025 | |
| Janssen Biotech, INC. | $139,596.21 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $27,262.91 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $22,575.71 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $12,304.10 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $9,732.34 | 2021-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $7,802.71 | 2021-2024 | Tremfya |
| Kowa Pharmaceuticals America, INC. | $5,363.25 | 2025 | Zoryve |
| Incyte Corporation | $2,586.03 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $2,153.57 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,977.94 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $1,906.31 | 2023-2025 | Adbry, Spevigo, Anzupgo |
| Sun Pharmaceutical Industries INC. | $1,125.88 | 2024-2025 | |
| Pfizer INC. | $1,007.93 | 2023-2025 | |
| Sanofi US Services INC. | $823.00 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $778.57 | 2023 | Cimzia |
| Sanofi-Aventis U.S. LLC | $300.90 | 2021-2022 | |
| Lilly USA, LLC | $205.81 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $162.36 | 2025 | Otezla |
| Almirall LLC | $22.05 | 2023 | Klisyri |
| Galderma Laboratories, L.P. | $14.68 | 2025 | Nemluvio |
| Paratek Pharmaceuticals, INC. | $13.75 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Arico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.